Left Ventricular Assist Devices and Heart Transplant

Left ventricular assist devices (LVADs) and heart transplantation represent the two most advanced interventions available for end-stage heart failure, a condition in which the heart can no longer sustain adequate circulation despite maximum medical and device therapy. This page covers the mechanical principles behind LVADs, the criteria governing transplant eligibility, the clinical scenarios that determine which intervention applies, and the regulatory and safety frameworks that govern both. Understanding the relationship between these two therapies is essential for grasping the full landscape of advanced heart failure and transplant cardiology.

Definition and scope

End-stage heart failure, classified as Stage D under the American Heart Association (AHA) and American College of Cardiology (ACC) four-stage framework (2022 AHA/ACC/HFSA Heart Failure Guidelines), affects an estimated 6.2 million adults in the United States (CDC, National Center for Health Statistics). At this stage, the left ventricle — the heart's primary pumping chamber — fails to maintain a cardiac output sufficient for tissue perfusion. Two durable mechanical and surgical options exist:

The two therapies are not mutually exclusive. LVADs frequently function as a bridge to transplantation, and the regulatory, surgical, and cardiological communities treat them as an integrated system of care rather than competing options.

How it works

LVAD mechanism

A continuous-flow LVAD consists of three primary components: an inflow cannula inserted into the left ventricular apex, a pump housing (implanted in the pericardial or pre-peritoneal space), and an outflow graft connected to the ascending aorta. A percutaneous driveline exits the skin and connects the pump to an external controller and power source.

Third-generation LVADs — such as the HeartMate 3, which received FDA premarket approval in 2017 — use a fully magnetically levitated centrifugal-flow impeller, eliminating mechanical bearings and reducing thrombotic risk compared to axial-flow predecessors. The FDA's Center for Devices and Radiological Health (CDRH) classifies LVADs as Class III medical devices requiring premarket approval (PMA) under 21 C.F.R. Part 814 (FDA PMA database).

Heart transplant mechanism

Orthotopic heart transplantation removes the recipient's failing heart, preserving the posterior walls of both atria (the bicaval technique). The donor heart, retrieved within a cold ischemic time window — ideally under 4 hours to minimize primary graft dysfunction — is anastomosed to the recipient's great vessels and atria. Post-transplant, lifelong immunosuppression is required, typically combining a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil), and corticosteroids, per the International Society for Heart and Lung Transplantation (ISHLT) guidelines (ISHLT Guidelines).

Common scenarios

Three distinct clinical scenarios govern LVAD use in relation to transplant:

  1. Bridge to transplantation (BTT): An LVAD is implanted in a listed transplant candidate to sustain hemodynamics while awaiting a donor organ. OPTN data show that a substantial proportion of heart transplant recipients in the United States underwent LVAD support prior to transplant.

  2. Destination therapy (DT): An LVAD is implanted as a permanent treatment in patients who are not transplant candidates due to age, comorbidities (e.g., advanced renal disease, active malignancy, severe pulmonary hypertension with fixed elevated pulmonary vascular resistance), or patient preference. FDA approved HeartMate II for destination therapy in 2010, expanding LVAD use beyond bridge applications.

  3. Bridge to decision (BTD): An LVAD is implanted in hemodynamically unstable patients whose transplant candidacy has not yet been determined — for example, patients with potentially reversible organ dysfunction secondary to low cardiac output. Stabilization on LVAD support allows reassessment of renal and hepatic function over weeks to months.

A fourth scenario — bridge to recovery — applies in select cases such as acute myocarditis or peripartum cardiomyopathy, where native ventricular recovery may allow LVAD explantation without transplant.

Decision boundaries

Selection between LVAD, transplant, or combined pathway depends on a structured, multidisciplinary evaluation. The regulatory context for cardiology shapes which institutions may perform these procedures, as CMS requires transplant centers to meet specific volume and outcome thresholds under Conditions of Participation (42 C.F.R. §482.102).

Key decision factors include:

  1. INTERMACS profile: The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) classifies patients on a 1–7 scale of hemodynamic instability. Profiles 1–2 (cardiogenic shock) typically require immediate mechanical circulatory support before any elective LVAD or transplant evaluation can proceed.

  2. Transplant contraindications: Irreversible pulmonary hypertension (pulmonary vascular resistance above 3 Wood units unresponsive to vasodilator challenge), active infection, severe obesity (BMI above 35 kg/m² at most programs), and malignancy within 5 years represent standard exclusion criteria, per ISHLT listing criteria.

  3. LVAD contraindications: Right ventricular failure severe enough to require biventricular support, inability to manage the driveline exit site (which carries an infection risk), and anatomic features precluding cannula placement limit LVAD candidacy.

  4. Donor organ availability: Median wait times on the OPTN heart transplant list vary by blood type and geographic OPTN region; the 2018 OPTN allocation policy change — prioritizing Status 1 and Status 2 candidates — significantly altered wait-time dynamics for LVAD-bridged patients.

The broader cardiology resource at cardiologyauthority.com covers the full spectrum of conditions and interventions that precede or accompany advanced heart failure management, including the upstream diagnoses of coronary artery disease and cardiomyopathy that most commonly lead to LVAD or transplant evaluation.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)